Vetter has cleared major development and verification milestones for V-OVS next, its next-generation syringe closure system, moving the product closer to commercial launch in 2027.
The globally operating contract development and manufacturing organization (CDMO) has finalized the design of V-OVS next and begun industrialization following a multi-cycle development process informed by extensive market feedback.
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats, expanding its applicability across ophthalmology, aesthetic injectables, diluents and biologics.
First unveiled at PharmaPack 2025, V-OVS next generated strong industry interest and has since progressed through key readiness steps. As part of industrialization, Vetter is now supplying its primary syringe glass partners with NFHU materials to support further testing and implementation across multiple syringe formats.
“With the first biopharma customers already giving positive feedback, we’re excited to see market uptake by some glass suppliers,” says Lars Hahn, Senior Vice President Global Sales Organization at Vetter. “We’ve already had successful conversations with multiple value chain partners and received consistently encouraging responses that reinforce our confidence in this launch.”
Vetter has also completed two critical internal verification milestones. A second Human Factors study and a Functional Study both delivered positive results for V-OVS next, building on an initial Human Factors study conducted earlier in 2025.
While the first study focused on user and product feedback, the second Human Factors study incorporated a use-related risk analysis to confirm safe and effective handling.
Participants evaluated usability and compared the system directly with the original V-OVS closure, confirming that V-OVS next offers a more user-friendly design with an enhanced user experience and a distinct look and feel.
In parallel, Vetter assessed the closure’s structural performance during manufacturing and handling. Initial testing showed that V-OVS next improves on the performance of the existing V-OVS, supports intuitive handling and reduces the likelihood of misuse.
“Our goal was to combine safety, usability, and design in a way that truly benefits the user of the system,” says Dr Claus Feussner, Senior Vice President Development Service at Vetter. “The positive results from both usability and performance evaluations confirm that V-OVS next delivers on these objectives.”
With development milestones met, Vetter will continue advancing V-OVS next towards its planned 2027 commercialization. Following launch, the company will offer both V-OVS and V-OVS next, giving customers flexibility across syringe-based products.
Both systems share the same contact materials and industry-standard tip cap rubber formulations, enabling straightforward upgrades for existing drugs and differentiation for new products.
